NovoCure (NVCR) Expected to Announce Earnings on Thursday

NovoCure (NASDAQ:NVCR - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Thursday, July 24th. Analysts expect the company to announce earnings of ($0.40) per share and revenue of $153.87 million for the quarter.

NovoCure (NASDAQ:NVCR - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The medical equipment provider reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.16. NovoCure had a negative net margin of 26.41% and a negative return on equity of 45.46%. The firm had revenue of $154.99 million for the quarter, compared to analysts' expectations of $147.57 million. During the same period in the prior year, the company posted ($0.36) earnings per share. The firm's quarterly revenue was up 11.9% on a year-over-year basis. On average, analysts expect NovoCure to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

NovoCure Stock Performance

NVCR stock traded down $0.19 during trading on Friday, hitting $16.02. 1,039,759 shares of the company's stock traded hands, compared to its average volume of 1,127,235. The company has a quick ratio of 1.41, a current ratio of 1.47 and a debt-to-equity ratio of 0.27. NovoCure has a 52 week low of $14.17 and a 52 week high of $34.13. The stock has a fifty day moving average price of $17.60 and a two-hundred day moving average price of $19.77. The stock has a market capitalization of $1.79 billion, a price-to-earnings ratio of -10.61 and a beta of 0.72.

Analysts Set New Price Targets

Several equities analysts have recently commented on NVCR shares. LADENBURG THALM/SH SH started coverage on shares of NovoCure in a research report on Tuesday, July 8th. They set a "buy" rating and a $30.00 price target for the company. JPMorgan Chase & Co. decreased their target price on shares of NovoCure from $29.00 to $28.00 and set a "neutral" rating for the company in a research report on Thursday, April 10th. Wall Street Zen lowered shares of NovoCure from a "hold" rating to a "sell" rating in a research report on Friday, April 25th. Piper Sandler reiterated an "overweight" rating and issued a $34.00 target price on shares of NovoCure in a research report on Friday, June 27th. Finally, Wedbush decreased their target price on shares of NovoCure from $29.00 to $27.00 and set a "neutral" rating for the company in a research report on Wednesday, April 16th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $32.43.

Institutional Trading of NovoCure

Hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. grew its holdings in NovoCure by 5.5% during the first quarter. Goldman Sachs Group Inc. now owns 993,670 shares of the medical equipment provider's stock valued at $17,707,000 after purchasing an additional 52,180 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in NovoCure by 3.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,992 shares of the medical equipment provider's stock worth $1,336,000 after purchasing an additional 2,502 shares during the period. AQR Capital Management LLC lifted its position in NovoCure by 56.7% in the first quarter. AQR Capital Management LLC now owns 28,728 shares of the medical equipment provider's stock worth $512,000 after purchasing an additional 10,394 shares during the period. Finally, Acadian Asset Management LLC bought a new position in shares of NovoCure during the first quarter valued at $87,000. 84.61% of the stock is owned by hedge funds and other institutional investors.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.